Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 19.75 AUD 3.51% Market Closed
Market Cap: 2.5B AUD

P/E
Price to Earnings

15.9
Current
17
Median
21.8
Industry
Lower than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
15.9
=
Market Cap
2.4B AUD
/
Net Income
149.1m AUD
All Countries
Close
Earnings Growth PEG
AU
Neuren Pharmaceuticals Ltd
ASX:NEU
Average P/E: 22.6
15.9
-29%
N/A
US
Eli Lilly and Co
NYSE:LLY
52.1
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
18%
1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
31%
0.5

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
139.4
2-Years Forward
P/E
45.5
3-Years Forward
P/E
46.8